Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 99-102

  Generali, Daniele ^a   Symmans, William F ^b   Berruti, Alfredo ^c   Fox, Stephen B ^d  

^a CREMONA HOSPITAL   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SAN LUIGI GONZAGA HOSPITAL   (Italy)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CASPASE 3; CD31 ANTIGEN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; EPIRUBICIN; ERYTHROPOIETIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HYPOXIA INDUCIBLE FACTOR; KI 67 ANTIGEN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BNIP3; PROTEIN KINASE B; PROTEIN P53; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR MARKER;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURGERY; CHEMOSENSITIVITY; CLINICAL EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT THERAPY; BREAST TUMOR; CELL HYPOXIA; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PREDICTIVE VALUE; PROGNOSIS; PROTEIN MICROARRAY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 84855175987     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr030     Document Type: Article

References (28)

1. Mori I, Yang Q, Kakudo K. Predictive and prognostic markers for invasive breast cancer. Pathol Int. 2002;52(3):186-194.
2. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52(1-3):261-288.
3. Bottini A, Berruti A, Brizzi MP, et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer. 2005;12(2):383-392.
4. Mele T, Generali D, Fox SB, et al. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Res Treat. 2010;123(3):795-804.
5. Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006;24(22):3623-3628.
6. Bottini A, Berruti A, Bersiga A, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res. 2000;6(7):2751-2758.
7. Nuyten DS, van de Vijver MJ. Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity. Semin Radiat Oncol. 2008;18(2):105-114.
8. Schmidt LH, Biesterfeld S, Kummel A, et al. Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res. 2009;29(1):201-209.
9. Generali D, Buffa FM, Berruti A, et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol. 2009;27(2):227-234.
10. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56(5):941-943.
11. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61(7):2911-2916.
12. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000;60(17):4693-4696.
13. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88(11):2606-2618.
14. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59(22):5830-5835.
15. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93(4):309-314.
16. Bos R, van Diest PJ, van der Groep P, et al. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res. 2004;6(4):R450-R459.
17. Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8(6):1831-1837.
18. Generali D, Berruti A, Brizzi MP, et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006;12(15):4562-4568.
19. Generali D, Fox SB, Berruti A, et al. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer. 2006;13(3):921-930.
20. Generali D, Fox SB, Berruti A, et al. Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clin Cancer Res. 2007;13(2 pt 1):550-558.
21. Generali D, Fox SB, Brizzi MP, et al. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res. 2008;14(9):2673-2680.
22. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373-5380.
23. Generali D, Bates G, Berruti A, et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res. 2009;15(3):1046-1051.
24. de Azambuja E, Cardoso F, de Castro G Jr., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504-1513.
25. Dowsett M, Smith IE, Ebbs SR. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99(2):167-170.
26. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319-1329.
27. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-e72.
28. Kaufmann M, Pusztai L. Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel. Cancer. 2011;117(8):1575-1582.